Antivascular endothelial growth factor therapies (anti-VEGF), ie, pegaptanib (Macugen®*), ranibizumab (Lucentis™*), bevacizumab (Avastin™), and aflibercept (Eylea™*), may be considered medically necessary as a treatment of neovascular (wet) age-related macular degeneration.
Antivascular endothelial growth factor therapies (anti-VEGF) may be considered medically necessary for the treatment of choroidal neovascularization due to angioid streaks, central serous chorioretinopathy, choroidal rupture or trauma, idiopathic choroidal neovascularization, multifocal choroiditis, pathologic myopia, presumed ocular histoplasmosis syndrome, and uveitis.
Antivascular endothelial growth factor therapies (anti-VEGF) are considered investigational for the treatment of chorioretinal scars.
* FDA-approved indication.
